GUJRATHI SHEILA
SEC insider (Form 3/4/5 filer). CIK 0001575202. Director at BlossomHill Therapeutics, Inc. (BLSM) and 3 other issuers. 7 reported Form 4/5 transactions since Sep 2024; latest on Jul 28, 2026. Located in VERO BEACH, FL.
Companies GUJRATHI SHEILA has filed insider reports for
- BlossomHill Therapeutics, Inc. (BLSM): Director
- Processa Pharmaceuticals, Inc. (PCSA): Director
- Ventyx Biosciences, Inc. (VTYX): Director
- Janux Therapeutics, Inc. (JANX): Director
GUJRATHI SHEILA
CIK: 0001575202
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Jul 28, 2026PCSA
Processa Pharmaceuticals, Inc.
AwardIndirectSeries A Preferred Stock
12.3K shares- - Jul 28, 2026PCSA
Processa Pharmaceuticals, Inc.
AwardDirectSeries A Preferred Stock
70.8K shares- - Mar 4, 2026VTYX
Ventyx Biosciences, Inc.
DispositionIndirect130K shares- - Jun 11, 2025JANX
Janux Therapeutics, Inc.
AwardDirect3.8K shares- - Jun 5, 2025VTYX
Ventyx Biosciences, Inc.
AwardDirectStock Option (Right to Buy)
40K shares- - Dec 23, 2024VTYX
Ventyx Biosciences, Inc.
PurchaseIndirect130K shares at avg. $2.31$301K - Nov 5, 2024JANX
Janux Therapeutics, Inc.
OtherDirect4.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 28, 2026 |  PCSA Processa Pharmaceuticals, Inc. | Award Series A Preferred Stock | 12,311 | - | - | Indirect |
| Jul 28, 2026 | PCSA Processa Pharmaceuticals, Inc. | Award Series A Preferred Stock | 70,812 | - | - | Direct |
| Mar 4, 2026 |  VTYX Ventyx Biosciences, Inc. | Disposition | 130,000 | - | $0 | Indirect |
| Jun 11, 2025 |  JANX Janux Therapeutics, Inc. | Award | 3,750 | - | - | Direct |
| Jun 5, 2025 | VTYX Ventyx Biosciences, Inc. | Award Stock Option (Right to Buy) | 40,000 | - | - | Direct |
| Dec 23, 2024 | VTYX Ventyx Biosciences, Inc. | Purchase | 130,000 | $2.31 | $300,573 | Indirect |
| Nov 5, 2024 | JANX Janux Therapeutics, Inc. | Other | 4,611 | - | $0 | Direct |
1-7 of 7 transactions